BioStock: CombiGene announces several milestones for CG01
Lund-based gene therapy company CombiGene continues to advance its main project CG01 ahead of the phase I studies scheduled to begin next year. The company is now ready for GMP production of drug substance and has also begun a collaboration with UK-based Neurochase in order to optimise the administration of the candidate.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se